| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
54,974 | 35,095 | 15,191 | ||||
General and administrative | ||||||
20,835 | 11,148 | 3,195 | ||||
Total operating expenses | ||||||
75,809 | 46,243 | 18,386 | ||||
Loss from operations | ||||||
-75,809 | -46,243 | -18,386 | ||||
Other income (expense): | ||||||
Interest income | ||||||
2,934 | 1,726 | 57 | ||||
Change in fair value of preferred stock warrant liability | ||||||
- | 162 | 17 | ||||
Change in fair value of derivative liability | ||||||
- | -1,629 | -283 | ||||
Other expense | ||||||
90 | 53 | 19 | ||||
Total other income (expense), net | ||||||
2,844 | -118 | -262 | ||||
Net loss | ||||||
-72,965 | -46,361 | -18,648 | ||||
Comprehensive loss | ||||||
-72,965 | -46,361 | -18,648 | ||||
Reconciliation of net loss to net loss attributable to common stockholders: | ||||||
Net loss | ||||||
-72,965 | -46,361 | -18,648 | ||||
Accretion of issuance costs on redeemable convertible preferred stock | ||||||
- | 2,243 | 85 | ||||
Net loss attributable to common stockholders—basic and diluted | ||||||
-72,965 | -48,604 | -18,733 | ||||
Net loss per share attributable to common stockholders—basic and diluted (Note 10) | ||||||
-2.66 | -3.62 | -8.38 | ||||
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders—basic and diluted | ||||||
27,432 | 13,435 | 2,235 | ||||